 |
 |

 Direct Medical Cost for Surgical and Medical Treatment of Condylomata Acuminata
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
We read with interest the article by Alam and Stiller,1
in particular the conclusions that they reach as to the cost advantages of
the treatment modalities considered for external genital warts (EGWs). We
have concerns about the article and the conclusions that were reached. The
methodology adopted by the authors is inappropriate with regard to the assessment
of cost-effectiveness in treating a disease such as EGWs, in which recurrence
is a critical issue. Regarding the article by Langley et al,2
we were concerned that the impact of high recurrence rates in EGW treatment
was only poorly understood and that physicians were accepting claims for cost-effectiveness
based on models of treatment that do not represent the decisions faced in
a real world environment. Unfortunately, Alam and Stiller explicitly exclude
any consideration of recurrence and the long-run efficacy of treatment, therapy
switching, and/or the use of combination therapy.3
As a result, their . . . [Full Text of this Article]
|